^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NXE0039732

    i
    Other names: NXE0039732, HTL0039732, HTL-0039732, NXE-0039732, NXE'732, HTL’732
    Associations

    News

    Trials
    Company:
    Cancer Research UK, Nxera Pharma
    Drug class:
    PGE4 antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    HTL0039732 in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Cancer Research UK | Trial primary completion date: Sep 2026 --> Jun 2027 | Trial completion date: Sep 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Tecentriq (atezolizumab) • NXE0039732
    over2years
    HTL0039732 in Participants With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=150, Recruiting, Cancer Research UK
    New P1/2 trial • Combination therapy • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 positive • MTOR mutation
    |
    Tecentriq (atezolizumab) • NXE0039732